Acute Myeloid Leukemia with Flt3 Mutation

• CLINICAL_TRIALS trial_result · 2025-09-12
  Clinical Trial Update: A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy [Phase 3]

  This Phase 3 trial evaluated gilteritinib alone or with azacitidine versus azacitidine alone in adults with newly diagnosed acute myeloid le…

• CLINICAL_TRIALS trial_result · 2025-05-31
  Clinical Trial Update: A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation

  A completed clinical trial assessed the safety of Xospata (gilteritinib) in patients with relapsed or refractory acute myeloid leukemia harb…

• CLINICAL_TRIALS trial_result · 2025-01-14
  Clinical Trial Update: A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation [Phase 3]

  Phase 3 trial comparing ASP2215 (gilteritinib) to salvage chemotherapy in relapsed or refractory acute myeloid leukemia with FLT3 mutation. …

• FDA approval · 2023-05-22
  FDA Approved: RYDAPT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  The FDA approved a supplemental application for RYDAPT (midostaurin) submitted by Novartis Pharmaceuticals Corporation. The approval updates…

• CLINICAL_TRIALS trial_result · 2022-06-24
  Clinical Trial Update: A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]

  Phase 1/2 trial evaluating the combination of gilteritinib and atezolizumab in relapsed or FLT3-mutated acute myeloid leukemia. The study is…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2021-04-20
  FDA Approved: RYDAPT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for RYDAPT (midostaurin) from Novartis, updating the regulatory status of the product.

• CLINICAL_TRIALS trial_result · 2019-08-07
  Clinical Trial Update: Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation [Phase 2]

  Phase 2 clinical trial investigating midostaurin plus decitabine in older adults with newly diagnosed AML and FLT3 mutation; study status te…

• FDA approval · 2018-06-21
  FDA Approved: RYDAPT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approves a supplemental application for RYDAPT (midostaurin) from Novartis Pharmaceuticals; the update expands or modifies the drug’s la…